Articles tagged with Sars
Severe COVID-19 and influenza infections can prime the lungs for cancer development, according to new research. Vaccination, however, largely prevents these changes, suggesting a reduced risk of lung cancer.
The American College of Chest Physicians (CHEST) has certified its first class of critical care advanced practice providers with the CCAPP designation. This achievement recognizes their dedication to high-quality patient care and their role in supporting multidisciplinary critical care teams. The CCAPP certification is designed to vali...
The new platform developed by UVA Health scientists can produce vaccines much faster, cheaper, and more easily than traditional approaches. The platform's proof-of-concept demonstrates its ability to produce highly immunogenic vaccines that can be manufactured at extremely low cost.
The American College of Chest Physicians (CHEST) received the 2025 Glenview Environmental Sustainability Award for Innovation, recognizing its commitment to clean energy and reduced emissions. The organization's solar panel installation at its headquarters powers medical simulation facilities using renewable energy.
A comprehensive review of pyridazinone derivatives reveals their therapeutic potential in treating multiple diseases. The compounds have shown anticancer, anti-inflammatory, antimicrobial, and neuroprotective properties, making them a valuable target for drug discovery.
The American College of Chest Physicians' CHEST Critical Care and CHEST Pulmonary journals have been indexed in Elsevier's Scopus database. This achievement is a testament to the high-quality research published in these journals, which provide open access content in pulmonary and critical care medicine.
The American College of Chest Physicians (CHEST) has developed an educational program and formal certification exam for nurse practitioners and physician assistants/associates in critical care. The program validates clinical expertise and demonstrates professional acumen, aiming to improve patient care.
The novel coronavirus SARS-CoV-2 has an enzyme that counteracts the innate defense mechanism against viruses, allowing it to evade the innate immune system and become more infectious. Understanding this mechanism may lead to the development of new antiviral drugs and treatments.
The American College of Chest Physicians' CHEST Critical Care and CHEST Pulmonary journals have been indexed with the Directory of Open Access Journals (DOAJ), enhancing their open access content's accessibility and usage. The indexation is attributed to strong editorial boards led by Hayley Gershengorn and Matthew Miles.
Researchers developed a new 'proactive vaccinology' approach to build vaccines before disease-causing pathogens emerge. The Quartet Nanocage vaccine trains the immune system to target specific regions of eight coronaviruses, providing broad protection against known and unknown strains.
Researchers document various reasons for long-term clinical symptoms in patients infected with SARS-CoV-2. Key findings include immune system alterations, chronic inflammation, endothelial dysfunction, and mitochondrial issues contributing to post-COVID syndrome.
A research team at the University of Göttingen has discovered 'protective switches' in the SARS-CoV-2 virus that shield it from attacks by the immune system. These molecular structures were found to stabilize the protein's structure against oxidative damage, allowing the virus to replicate effectively.
A study of 170 COVID-19 patients with severe ARDS found that prone positioning compared to supine positioning did not significantly reduce the time to successful weaning from ECMO. The study suggests that other factors may influence ECMO weaning outcomes.
A new study found that voluntary collective isolation was unlikely to prevent rapid spread of COVID-19 among the Tsimané, a small-scale Indigenous society in remote Amazonia. The simulation predicted nearly identical rates of infection in real-world data, highlighting the need for targeted interventions and medical resources
A growing number of studies highlights the power of dogs in detecting COVID-19 and its variants, even when obscured by other viruses. Trained scent dogs are as effective and often more effective than antigen tests and RT-PCR tests, detecting the virus faster and without environmental impact.
Researchers at TUM develop an RNA agent for a lung spray that slows macrophage activity, reducing lung inflammation and fibrosis. The active substance RCS-21 is delivered via an inhaler through a special sugar molecule, showing promise in treating acute inflammatory lung damage.
The inaugural issue of CHEST Critical Care focuses on clinically relevant research and patient management guidance for critical care medicine. The journal accepts submissions of original research, case series, and research letters, covering topics such as intensive care medicine and diverse populations.
Researchers found a link between short telomeres in ATII cells and lung fibrosis in post-COVID-19 patients. The study revealed loss of ATII cellularity and shorter telomeres concomitant with increased fibrotic lung parenchyma remodeling.
The June issue of CHEST features 49 articles on clinically relevant topics, including asthma, COPD, and critical care. The journal offers web and multimedia resources to expand the reach of its research.
Researchers at Texas Biomedical Research Institute have developed a new cell culture model to generate human alveolar macrophages, the most critical immune cells in the lungs. This model allows for easier and inexpensive investigation of lung inflammatory diseases and testing of new therapies.
The January issue of the CHEST journal features a range of clinically relevant research on COPD, bronchiectasis, and pulmonary vascular disease. The journal's education portal offers continuing medical education (CME) credit for select articles.
A new study uses serial femtosecond X-ray crystallography to reveal the structure of NendoU protein at room temperature. The resulting high-resolution image shows that the protein's flexibility plays a crucial role in its functional mechanism, which is essential for designing antiviral drugs against SARS-CoV-2.
The December issue of CHEST journal features articles on COVID-19 lessons learned and future pandemic preparedness. The journal also explores various topics in chest medicine, including asthma, critical care, and sleep medicine.
New research reveals that bat virus relatives of MERS-CoV efficiently bind to bat ACE2 receptors as an entry point into cells. However, these viruses only weakly bind to human ACE2 cell receptors and are not known to cause disease outbreaks in people.
A University of Ottawa-led team identified a new entry route for SARS-CoV-2 using metalloproteinases, which may lead to more widespread cell infection and severe illness. The study suggests that variants like the Delta strain may prefer this entry method, while others like Omicron do not.
Dr. Fauci highlights the rapid development and distribution of COVID-19 vaccines as a significant success in responding to emerging infectious diseases. He emphasizes the need to improve capabilities for established diseases like malaria and tuberculosis while addressing new threats.
Researchers found that treatment with remdesivir within 9 days of symptom onset decreases mortality in Japanese patients with severe to critical COVID-19 who received corticosteroids. The study suggests early treatment with remdesivir and corticosteroids is associated with decreased mortality.
Researchers at Jacobs University have found that a compound in coffee, 5-caffeoylquinic acid, can inhibit the interaction between the SARS-CoV-2 spike protein and the ACE-2 receptor, potentially providing protection against COVID-19. The study's findings suggest that regular coffee drinkers may be less likely to contract the virus.
The October issue of CHEST journal showcases 43 clinically relevant articles on topics such as asthma, COPD, critical care, and sleep medicine. The journal also offers web and multimedia activities, including visual abstracts, to expand its reach.
A team of UCF researchers has developed a nanomaterial-based disinfectant that can kill several serious viruses, including SARS and Zika. The disinfectant uses white light activation to regenerate its antiviral properties, making it effective in minimizing surface-to-surface spread of viruses.
Researchers from Trinity College Dublin have discovered how SARS and MERS coronaviruses block the induction of antiviral proteins, preventing a strong immune response. This finding has potential implications for developing new therapeutic options to treat COVID-19 and future deadly coronaviruses.
A new study assesses wastewater infrastructure in 129 countries to explore community-wide health indices using Wastewater-based Epidemiology (WBE). The technique detects factors influencing health, including disease biomarkers detectable in wastewater.
Scientists at University of Illinois and Mie University develop monoclonal antibodies to prevent lung cell death in mouse models of idiopathic pulmonary fibrosis and acute respiratory disease syndrome. Non-invasive diagnostic tools also presented could aid in predicting disease progression and identifying patients at risk.
A UC Riverside-led study has identified a potential antiviral therapy for SARS and SARS-like coronaviruses by targeting the papain-like protease enzyme. The research reveals that subgroup 2b PLpros selectively target specific host immune pathways, making them a promising target for future coronavirus therapeutics.
Dr. Edward Y. Lee, MD, MPH, receives the highest distinction from North America's first radiological society for his contributions to pediatric thoracic imaging and education. The ARRS Gold Medal honors his tireless efforts to advance radiology globally.
Researchers have discovered unique antibody-like proteins from sharks that can prevent the COVID-19 virus and its variants from infecting human cells. These shark-derived protein 'VNARs' are a promising new tool in the fight against SARS-CoV-2, with potential applications for future coronavirus outbreaks.
A clinical trial has revealed that COVID-19 patients on ventilators have less surfactant in their lungs due to the virus. The researchers suggest that giving extra surfactant for a longer period could help save lives by supporting breathing and allowing lung cells to repair after the infection passes.
A study published in PLOS Computational Biology found that rodents have a greater diversity and accelerated rate of evolution in the ACE2 receptors used by SARS viruses. This suggests that some rodent species may be asymptomatic carriers of SARS-like coronaviruses, potentially leading to new pathogen transmission to humans.
A new study published in PLOS ONE found that over half of surveyed healthcare workers reported PTSD symptoms during the COVID-19 pandemic, regardless of previous SARS experience. Healthcare workers with prior SARS experience showed lower scores of PTSD and depression, but this effect disappeared after correcting for other factors.
Researchers found that levels of chitinase 3-like-1 increase with age and co-morbid diseases, augmenting SARS-CoV-2 infection. A therapeutic antibody blocks the induction of the ACE2 receptor, potentially paving the way for COVID-19 prevention and treatment.
Researchers at Shanghai Institute of Materia Medica have isolated and characterized seven novel dimeric sesquiterpenoids with potent antimalarial activities. The most potent compound, Shizukaol A, exhibits an EC50 value 1000-fold more active than artemisinin.
Researchers found that Delta and Delta Plus infect lung cells with higher efficiency than the original virus, evading antibodies induced by infection and vaccination. The new variants were also resistant to some therapeutic antibodies, leading to reduced inhibition.
A study by Northwestern University scientists has shown that coronavirus vaccines and prior infections can provide broad immunity against other, similar coronaviruses. The findings build a rationale for universal coronavirus vaccines.
Researchers at the University of California - San Diego have developed COVID-19 vaccine candidates made from plant viruses and bacteriophages, which can be stored and shipped without refrigeration. These vaccines trigger high production of neutralizing antibodies in mice, offering a potential solution for global distribution efforts.
A new study found that vaccinated SARS survivors can produce antibodies capable of neutralizing not only current but also future coronavirus threats. The breakthrough could lead to the development of an effective, broad-spectrum vaccine against different coronaviruses.
Ting Zou, a postdoctoral fellow at The University of Hong Kong, has been awarded the IADR Toshio Nakao Fellowship for her research on multifunctional hydrogels and tissue regeneration.
May Wong, Professor of Dental Public Health at the University of Hong Kong, was awarded the IADR Distinguished Scientist H. Trendly Dean Memorial Award for her significant contributions to dental research. Her work focuses on biostatistics, oral epidemiology, and clinical trials.
A study by Environmental Working Group (EWG) recommends stringent health-based exposure standards for radiofrequency radiation emitted from wireless devices. EWG suggests that children's exposure should be 200 to 400 lower than the whole-body exposure limit set by the FCC in 1996.
Patients with five or more symptoms of COVID-19 in the first week are more likely to develop long COVID. The review highlights ten common symptoms, including fatigue and shortness of breath, which may indicate a higher risk of developing long COVID.
A Mayo Clinic study reports on the first 100 patients with post-COVID-19 syndrome, experiencing symptoms like fatigue, respiratory complaints, and neurologic issues. The study highlights the need for healthcare providers to prepare for prolonged symptoms and provide effective treatment, including psychosocial support.
New research using Synthetic Aperture Radar data from Sentinel-1 satellites shows improved ability to detect, monitor, prepare for and withstand natural disasters like bushfires and floods. SAR data provides valuable insights for hazard mitigation and complementing existing Earth observation programs.
SARS coronaviruses enhance protein production in infected cells, leading to increased viral replication. The unique domain of the virus interacts with human Paip-1, binding to ribosomes and promoting viral protein synthesis.
A new study explores the role of MHC-I variants in SARS CoV-2 infection, finding that certain alleles are better at binding viral fragments and stimulating a strong immune response. This knowledge may help predict individual susceptibility and inform vaccine development.
Researchers developed an effective environmental monitoring methodology for SARS CoV-2 virus, detecting viral RNA persistence on surfaces for at least 8 days. The study found that a minimum of 1,000 viral particles per 25 cm2 are required to detect the virus effectively.
A new report suggests that COVID-19 survivors may be experiencing 'brain fog' and other neurological symptoms due to post-traumatic stress disorder (PTSD). The study, published in The Clinical Neuropsychologist, explores historical data on previous coronaviruses and finds a heightened risk of PTSD among survivors. Researchers emphasize...
A randomized clinical trial found that intravenous dexamethasone plus standard care increased the number of days patients were alive and free from mechanical ventilation. The study involved 299 patients with moderate or severe acute respiratory distress syndrome due to COVID-19, and the results suggest a potential treatment benefit.
Scientists have identified a highly conserved envelope protein in both SARS-CoV-2 and SARS-CoV-1, which could be targeted with existing drugs to prevent acute respiratory distress syndrome. Researchers plan to conduct trials using FDA-approved medications and aim to utilize their data for vaccine design.
A new review finds that COVID-19 can cause damage to the endocrine system, leading to worsening of existing conditions and increased risk of diabetes. Steroids may be a crucial treatment option for patients with COVID-19, as recent studies have shown improved mortality rates in severely ill patients treated with dexamethasone.
Researchers will use ICM Pro software and X-ray crystallography to analyze SARS-CoV-2 proteins and identify potential therapeutic drug candidates. This work aims to provide a head start in combating future pandemics by understanding the biology of coronaviruses.
A team of UGA scientists has successfully demonstrated that a set of drug-like small molecules can block the activity of the SARS-CoV-2 protein PLpro, providing a promising path for new COVID-19 therapeutics. The discovery offers a potential rapid development path to generating PLpro-targeted therapeutics for use against SARS-CoV-2.